Merit Medical Systems stock (US59001A1025): Director sells $313K in shares

Merit Medical Systems director Lynne Ward sold 5,000 shares worth $313,035 on May 7, 2026, per SEC filing. Meanwhile, the chief legal officer bought shares via 401(k). Stock trades on Nasdaq.

Merit Medical Systems director Lynne N. Ward sold 5,000 shares of company stock on May 7, 2026, for approximately $313,035, according to an SEC filing reported by MarketBeat as of 05/11/2026. This insider transaction follows recent earnings where Q1 revenue hit $381.9 million, beating estimates. The stock is listed on Nasdaq under MMSI.

As of: 12.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Merit Medical Systems, Inc
• Sector/industry: Medical devices
• Headquarters/country: United States
• Core markets: Diagnostic and interventional procedures
• Key revenue drivers: Disposable medical devices
• Home exchange/listing venue: Nasdaq (MMSI)
• Trading currency: USD

Merit Medical Systems: core business model

Merit Medical Systems designs, manufactures and markets disposable medical devices used in interventional, diagnostic and cardiac procedures worldwide. The company focuses on cardiology, radiology, vascular, endoscopy, neuroscience and general surgery markets, according to its investor relations site. Products include inflation devices, catheters and guidewires.

Headquartered in South Jordan, Utah, Merit Medical serves healthcare providers globally with single-use devices that enhance procedure safety and efficiency. The business model emphasizes innovation in minimally invasive technologies, supporting growth in outpatient procedures relevant to US investors tracking medtech trends.

Main revenue and product drivers for Merit Medical Systems

Key revenue comes from peripheral interventions, cardiac interventions and endoscopy segments. In Q1 2026, revenue reached $381.9 million, surpassing FactSet estimates of $377.6 million, as reported by MarketScreener on 05/11/2026. The company guided 2026 revenue at $1.61-$1.63 billion, aligning with consensus.

Products like the TIF 2.0 system for GERD treatment drive endoscopy growth, per the company website. Cardiovascular devices remain core, benefiting from rising US demand for interventional cardiology amid an aging population.

Industry trends and competitive position

The medical devices sector sees strong demand for disposable products post-COVID, with US market growth projected at 5-7% annually per sector reports. Merit Medical competes with players like Boston Scientific in niche interventional tools, holding a solid position in custom kits and kits for procedure trays.

Why Merit Medical Systems matters for US investors

As a Nasdaq-listed medtech firm with US headquarters, Merit Medical offers exposure to domestic healthcare spending, which accounts for nearly 18% of GDP. Its focus on high-margin disposables aligns with trends in elective procedures rebounding in the US.

Conclusion

Recent insider sales by a director contrast with a CLO purchase, amid solid Q1 results and full-year guidance. Merit Medical Systems continues advancing in medtech disposables, with Nasdaq listing providing liquidity for US investors. Market reactions and future earnings will shape the trajectory.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.